Overview

A Study to Examine the Safety, Pharmacokinetics and Pharmacodynamics of Single Dose of AMG 623 in Subjects With Systemic Lupus Erythematosus

Status:
Completed
Trial end date:
2007-06-01
Target enrollment:
Participant gender:
Summary
This study is to evaluate the safety of AMG 623 in subjects with systemic lupus erythematosus. The study consists of a 21 day screening period followed by administration of the investigational product and up to 70 day follow up period.
Phase:
Phase 1
Details
Lead Sponsor:
Amgen